← Back to Calendar

Cytokinetics Q1 2026 Earnings

Cytokinetics · $CYTK

Standard Review Earnings

PDUFA Date

May 6, 2026

Time Remaining

43 days

Review Type

Standard (10 mo)

Indication

Q1 2026 earnings + MYQORZO launch metrics + ACACIA-HCM update

Key Notes

Q1 2026 earnings expected May 6, 2026. First full quarter of MYQORZO commercial launch. Key data: market share vs BMS Camzyos, patient uptake, reimbursement access. ACACIA-HCM (non-obstructive HCM) readout expected Q2 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar